title: Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer.
abstract: OBJECTIVE
  The objective of this study is to determine whether 2-deoxy-2-[18F] fluoro-D: -glucose with positron emission tomography (FDG-PET) imaging and quantitative PET parameters can predict outcome and differentiate patients with limited disease (LD) from extensive disease (ED) in patients with small cell lung cancer (SCLC).
  
  
  METHODS
  We retrospectively evaluated data from 25 patients who underwent either initial staging (Group A, n 12) or restaging (Group B, n 13) by conventional imaging methods and FDG-PET according to the simplified staging scheme developed by the Veterans Administration Lung Cancer Study Group-2. FDG-PET images were both visually and quantitatively evaluated with SUV(max), SUV(ave), total metabolic tumor volume (with SUV(max) > %50 and SUV(max) > 2.5), total lesion glycolysis (TLG) (with SUV(max) > %50 and SUV(max) > 2.5). The correlation between quantitative PET parameters, disease stages and survival were analyzed.
  
  
  RESULTS
  By conventional methods 14 of 25 (56%) patients were reported to have LD and 11 of 25 (44%) had ED. FDG-PET scan upstaged 9 out of 25 (36%) and downstaged 2 out of 25 (%8) patients. Among the quantitative PET parameters, TLGs were the only PET parameters that differentiated between Group A and Group B patients. FDG-PET staging (p = 0.019) could predict significant survival difference between stages on contrary to conventional staging (p = 0.055). Moreover, TLG [SUV(max) > %50] was the only quantitative PET parameter that could predict survival (p = 0.027).
  
  
  CONCLUSIONS
  FDG-PET imaging is a valuable tool in the management of patients with SCLC for a more accurate staging. The use of quantitative PET parameters may have a role in prediction of stage and survival.
authors.affiliation: Department of Nuclear Medicine, Gülhane Military Medical Academy and Medical Faculty, Ankara, Turkey. narslan@gata.edu.tr
authors.forename: Nuri
authors.initials: N
authors.lastname: Arslan
authors.forename: Murat
authors.initials: M
authors.lastname: Tuncel
authors.forename: Okan
authors.initials: O
authors.lastname: Kuzhan
authors.forename: Engin
authors.initials: E
authors.lastname: Alagoz
authors.forename: Burcin
authors.initials: B
authors.lastname: Budakoglu
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ozet
authors.forename: Mehmet Ali
authors.initials: MA
authors.lastname: Ozguven
mesh_terms: D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011379:Prognosis; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000000981:diagnostic imaging* / Q000473:pathology*; D016019:Survival Analysis
chemical_list: D019788:Fluorodeoxyglucose F18